Production of a novel humanised anti Dendritic Cell Therapeutic Antibody for Graft Versus Host Disease

从捐赠者身上移植骨髓或其他来源的血液干细胞通常用于治疗对化疗无效的白血病患者。Mater医学研究所已经开发出世界上第一个树突状细胞耗竭治疗性抗体，这可能为控制急性移植物抗宿主病开辟新的策略，急性移植物抗宿主病是骨髓移植非常常见且往往是致命的并发症。这种新的抗体疗法也可能有助于防止实体器官移植的排斥反应。如果成功，它将选择性地控制移植物抗宿主疾病，而不会损害移植物的基本抗病毒免疫和所需的抗白血病活性。

A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.